Amneal Pharmaceuticals Inc (AMRX) has a current Price-to-Book (P/B) ratio of -36.35. Compared to its 3-year average P/B ratio of -10.38, the current P/B ratio is approximately 250.12% higher. Relative to its 5-year average P/B ratio of -5.27, the current P/B ratio is about 589.81% higher. Amneal Pharmaceuticals Inc (AMRX) has a Forward Free Cash Flow (FCF) yield of approximately 6.27%. Compared to its 3-year average FCF yield of 12.04%, the current FCF yield is approximately -47.91% lower. Relative to its 5-year average FCF yield of 18.90%, the current FCF yield is about -66.81% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AMRX competitors is 23.45, providing a benchmark for relative valuation. Amneal Pharmaceuticals Inc Corp (AMRX.N) exhibits a P/S ratio of 1.26, which is -94.61% above the industry average. Given its robust revenue growth of 11.47%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AMRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AMRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AMRX currently overvalued or undervalued?

What is Amneal Pharmaceuticals Inc (AMRX) fair value?

AMRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Amneal Pharmaceuticals Inc (AMRX) is between 11.11 to 16.18 according to relative valuation method.

How does AMRX's valuation metrics compare to the industry average?

The average P/S ratio for AMRX's competitors is 23.45, providing a benchmark for relative valuation. Amneal Pharmaceuticals Inc Corp (AMRX) exhibits a P/S ratio of 1.26, which is -94.61% above the industry average. Given its robust revenue growth of 11.47%, this premium appears unsustainable.

What is the current P/B ratio for Amneal Pharmaceuticals Inc (AMRX) as of Mar 02 2026?

As of Mar 02 2026, Amneal Pharmaceuticals Inc (AMRX) has a P/B ratio of -36.35. This indicates that the market values AMRX at -36.35 times its book value.

What is the current FCF Yield for Amneal Pharmaceuticals Inc (AMRX) as of Mar 02 2026?

As of Mar 02 2026, Amneal Pharmaceuticals Inc (AMRX) has a FCF Yield of 6.27%. This means that for every dollar of Amneal Pharmaceuticals Inc's market capitalization, the company generates 6.27 cents in free cash flow.

What is the current Forward P/E ratio for Amneal Pharmaceuticals Inc (AMRX) as of Mar 02 2026?

As of Mar 02 2026, Amneal Pharmaceuticals Inc (AMRX) has a Forward P/E ratio of 15.11. This means the market is willing to pay $15.11 for every dollar of Amneal Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Amneal Pharmaceuticals Inc (AMRX) as of Mar 02 2026?

As of Mar 02 2026, Amneal Pharmaceuticals Inc (AMRX) has a Forward P/S ratio of 1.26. This means the market is valuing AMRX at $1.26 for every dollar of expected revenue over the next 12 months.

AMRX Valuation